Non-Hodgkins Lymphoma also known as NHL is a heterogeneous and complex group of disorders that are characterized by clonal proliferation of lymphocytes at multiple stages of maturation. There are approximately 30 types of NHLs with varying pathological, clinical, and genetic features. Chronic Lymphoma (CLL) is a neoplasm of monomorphic small, round lymphocytes of B cell origin in 98% of the cases.
This report contains market size and forecasts of Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatment in Global, including the following market information:
Global Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
B-Cell Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatment include F. Hoffmann La-Roche Ltd., Johnson & Johnson, Bayer AG, Eli Lilly and Company, Amgen, Inc., Novartis AG, Gilead, Kite Pharma, Inc. and GlaxoSmithKline Plc and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatment Market Segment Percentages, by Type, 2021 (%)
B-Cell
T-Cell
Global Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatment Market Segment Percentages, by Application, 2021 (%)
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Stem Cell Transplant
Global Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
F. Hoffmann La-Roche Ltd.
Johnson & Johnson
Bayer AG
Eli Lilly and Company
Amgen, Inc.
Novartis AG
Gilead
Kite Pharma, Inc.
GlaxoSmithKline Plc
Bristol-Myers Squibb